Brown Advisory Securities LLC purchased a new stake in shares of Medidata Solutions Inc (NASDAQ:MDSO) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 5,630 shares of the company’s stock, valued at approximately $356,000.
Several other hedge funds have also modified their holdings of the company. Royce & Associates LP grew its stake in Medidata Solutions by 45.6% in the fourth quarter. Royce & Associates LP now owns 416,017 shares of the company’s stock valued at $26,363,000 after purchasing an additional 130,352 shares in the last quarter. UBS Asset Management Americas Inc. grew its stake in Medidata Solutions by 4.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 37,821 shares of the company’s stock valued at $2,397,000 after purchasing an additional 1,639 shares in the last quarter. Schroder Investment Management Group purchased a new position in Medidata Solutions in the fourth quarter valued at about $626,000. Polen Capital Management LLC grew its stake in Medidata Solutions by 77.0% in the fourth quarter. Polen Capital Management LLC now owns 4,640 shares of the company’s stock valued at $294,000 after purchasing an additional 2,018 shares in the last quarter. Finally, Arizona State Retirement System grew its stake in Medidata Solutions by 27.1% in the fourth quarter. Arizona State Retirement System now owns 42,079 shares of the company’s stock valued at $2,667,000 after purchasing an additional 8,965 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.
In related news, CFO Rouven Bergmann sold 2,000 shares of the business’s stock in a transaction dated Tuesday, December 19th. The stock was sold at an average price of $65.95, for a total transaction of $131,900.00. Following the completion of the transaction, the chief financial officer now owns 89,775 shares of the company’s stock, valued at approximately $5,920,661.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Carlos Dominguez sold 9,066 shares of the business’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $66.85, for a total value of $606,062.10. Following the transaction, the director now directly owns 66,020 shares of the company’s stock, valued at approximately $4,413,437. The disclosure for this sale can be found here. Insiders have sold a total of 18,066 shares of company stock valued at $1,211,682 in the last three months. 5.80% of the stock is owned by insiders.
Shares of Medidata Solutions Inc (NASDAQ:MDSO) opened at $67.50 on Thursday. Medidata Solutions Inc has a 12-month low of $54.36 and a 12-month high of $85.92. The firm has a market capitalization of $3,984.10, a PE ratio of 91.22, a price-to-earnings-growth ratio of 3.44 and a beta of 1.58. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.50 and a quick ratio of 3.37.
Medidata Solutions (NASDAQ:MDSO) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.10. Medidata Solutions had a return on equity of 11.59% and a net margin of 8.14%. The business had revenue of $141.20 million during the quarter, compared to analysts’ expectations of $140.65 million. During the same quarter in the previous year, the firm earned $0.33 EPS. The firm’s revenue was up 13.4% compared to the same quarter last year. sell-side analysts expect that Medidata Solutions Inc will post 0.97 EPS for the current fiscal year.
A number of brokerages have commented on MDSO. SunTrust Banks restated a “buy” rating and issued a $92.00 target price on shares of Medidata Solutions in a research note on Friday, October 27th. Wells Fargo & Co reduced their price target on Medidata Solutions from $83.00 to $80.00 and set a “market perform” rating for the company in a research report on Friday, October 27th. Zacks Investment Research cut Medidata Solutions from a “hold” rating to a “sell” rating in a research report on Thursday, November 2nd. Dougherty & Co initiated coverage on Medidata Solutions in a research report on Thursday, November 2nd. They issued a “neutral” rating for the company. Finally, Royal Bank of Canada reaffirmed a “hold” rating and issued a $80.00 price target on shares of Medidata Solutions in a research report on Friday, October 27th. Four research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $82.07.
ILLEGAL ACTIVITY WARNING: “Brown Advisory Securities LLC Purchases Shares of 5,630 Medidata Solutions Inc (MDSO)” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/22/brown-advisory-securities-llc-purchases-shares-of-5630-medidata-solutions-inc-mdso.html.
Medidata Solutions Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Want to see what other hedge funds are holding MDSO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medidata Solutions Inc (NASDAQ:MDSO).
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.